The 7 major Tay-Sachs disease markets are expected to exhibit a CAGR of 4.56% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2034
|
Historical Years
|
2018-2023
|
Market Growth Rate 2024-2034 | 4.56% |
The Tay-Sachs disease market has been comprehensively analyzed in IMARC's new report titled "Tay-Sachs Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tay-Sachs disease refers to a rare genetic disorder that primarily affects the nervous system. It is caused by a deficiency in the hexosaminidase A enzyme, which leads to the accumulation of a fatty substance called GM2 ganglioside in the nerve cells of the spinal cord and brain. The symptoms of this condition typically appear in the first few months of life and progress rapidly. Infants suffering from Tay-Sachs disease may experience developmental delays, progressive weakness, loss of muscle tone, an exaggerated startle response to sudden noises, an inability to move their eyes, etc. Numerous other common indications of the ailment may include seizures, difficulty swallowing, and, eventually, a loss of vision and hearing. The diagnosis of this illness requires a combination of the patient's clinical features, medical and family history, along with a physical and eye examination. A healthcare provider may also perform genetic testing to determine changes in the genome responsible for underlying symptoms. Furthermore, several blood workups to check the hexosaminidase A enzyme levels in the blood are recommended.
The rising incidences of DNA alterations, gene abnormalities, and chromosomal damage due to inherited disorders are primarily driving the Tay-Sachs disease market. Moreover, the widespread adoption of effective drugs, such as anti-seizures and antibiotics, to ease the symptoms and prevent the progression of the ailment is also augmenting the market growth. Apart from this, the inflating utilization of prenatal testing for Tay-Sachs disease through chorionic villi sampling or amniocentesis, which can reveal gene mutations associated with the condition and facilitate early detection in patients, is further creating a positive outlook for the market. Additionally, the escalating demand for occupational and physical therapies, owing to their numerous benefits like maintained joint flexibility, enhanced range of motion, delayed loss of muscular functions, improved daily activities, etc., is acting as another significant growth-inducing factor. Besides this, the growing popularity of gene therapy, that aims at permanent correction of the genetic defect, thereby allowing more effective and long-lasting therapeutic results than other conventional therapies, is expected to drive the Tay-Sachs disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Tay-Sachs disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Tay-Sachs disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Tay-Sachs disease market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current Tay-Sachs disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Market Insights
Epidemiology Insights
Tay-Sachs Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies